TWiV 657: Shane Crotty on SARS-CoV-2 immunity
Immunologist Shane Crotty joins TWiV to discuss the antibody and T cell responses to infection with SARS-CoV-2, followed by answers to listener questions.
vaccine
TWiV 655: Minority health with Robert Fullilove
Sociomedical scientist Robert Fullilove joins TWiV to discuss disparities in minority health; FDA announces an EUA on Yale’s SalivaDirect, protection of the upper and respiratory tract of mice after intranasal inoculation with an adenovirus-vectored SARS-CoV-2 spike gene, and listener questions. Click arrow to playDownload TWiV 655 (88 MB .mp3, 147 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become a patron of TWiV! Show …
The future of SARS-CoV-2
What does the future hold for SARS-CoV-2? Will it remain in its current configuration, with 20% of infections causing serious damage? Will everyone on Earth need to be vaccinated regularly to prevent infection? Allow me to indulge in some speculation and suggest that SARS-CoV-2 will eventually become the fifth common cold coronavirus (CoV). There are …
TWiV 651: FDA rules with Denise Esposito
Daniel Griffin provides a clinical report on COVID-19, then former FDA Chief of Staff to the Commissioner Denise Esposito joins us to explain the challenges in approving vaccines, antiviral drugs, and diagnostic tests during a pandemic, followed by answers to listener questions. Click arrow to playDownload TWiV 651 (98 MB .mp3, 164 min)Subscribe (free): iTunes, Google Podcasts, RSS, email Become …
TWiV 648: Life is for learning
Daniel Griffin provides a clinical report on COVID-19, followed by a review of the findings that children shed as much SARS-CoV-2 viral RNA from the respiratory tract as older patients, the lineage giving rise to SARS-CoV-2 has been circulating in bats in China for decades, and answers to listener questions. Click arrow to playDownload TWiV 648 …
Preliminary phase I/II results of ChAdOx1 SARS-CoV-2 vaccine
by Gertrud U. Rey On July 20, 2020, Oxford University’s Jenner Institute and the pharmaceutical company AstraZeneca reported preliminary results from phase I/II clinical trials assessing the safety and efficacy of a vaccine candidate against SARS-CoV-2. The vaccine candidate, named AZD1222 (referred to in the publication as ChAdOx1 nCoV-19), consists of an adenovirus vector with an …
Preliminary phase I/II results of ChAdOx1 SARS-CoV-2 vaccine Read More »